GlassScriptPhysician profile
Jessica Pack
NPI 1629609359
$3,511.24
in general payments reported to CMS, 2019-2025
24 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $509 · 2023: $487 · 2024: $642 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.91 | 2021-2025 | |
| Novo Nordisk INC | $397.39 | 2021-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $357.39 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $330.69 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $218.74 | 2024-2025 | Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $197.34 | 2022 | |
| Glaxosmithkline, LLC. | $166.65 | 2021-2024 | Arexvy |
| Medtronic, INC. | $163.28 | 2021-2023 | Minimed 780g |
| Sk Life Science, INC. | $138.22 | 2021-2023 | Xcopri |
| Lundbeck LLC | $121.48 | 2025 | Vyepti |
| Phathom Pharmaceuticals, INC. | $112.53 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.12 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $110.38 | 2025 | Capvaxive |
| Alexion Pharmaceuticals, INC. | $93.17 | 2024 | |
| Argenx US, INC. | $87.73 | 2025 | Vyvgart |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $86.97 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $85.53 | 2023 | Jynarque |
| Biogen, INC. | $70.94 | 2023 | |
| Beta Bionics, INC. | $69.97 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Grifols USA, LLC | $58.34 | 2024 | Prolastin-C Liquid |
| Pfizer INC. | $53.45 | 2023 | |
| Janssen Pharmaceuticals, INC | $37.50 | 2022 | |
| Csl Behring | $25.09 | 2024 | Kcentra |
| Ipsen Biopharmaceuticals, INC | $19.43 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.